(MP78-06) Testosterone treatment prevents progression from prediabetes to Type 2 Diabetes (T2DM) in 303 hypogonadal men: 14-year real-life data from a registry

Aksam Yassin 1,2,3, Mohammed Mahdi* 1, Mustafa Alwani4, Riad Talib1, Abdel Rahman Jaber1, and Khalid Alrumaihi1

- ¹ Department of Urology, Hamad General Hospital, HMC, Doha, Qatar,
- ² Institute for Urology and Andrology, Norderstedt, Germany,
- 3 Dresden International University, Dresden, Germany
- 4 University of science and technology, school of medicine, Irbid, Jordan

☐ Introduction & Objectives:

Men with hypogonadism are at increased risk for developing insulin resistance (IR), prediabetes and type 2 diabetes.

**(p<0.0001)

Does testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D?


■ Methods:

- Pooled Data of 303 men with hypogonadism,
- Treatment group (T-group): 220 men (TU;T-group),
- Control group: 83 men (CTRL).
- Anthropometric and metabolic parameters were measured.

Changes in fasting glucose, HgbA1c, weight, TG:HDL ratio, TyG index, LAF, Testosterone, AMS scale

results: Mean follow-up: 6.6 years (T-group), 5.6 years (CTRL)

		T- group	CTRL
,	HgA1c	from 5.9±0.2 to 5.5±0.3%	↑ from 5.9±0.2 to 6.1±0.6%*
	TyG index	↓from 9.3±0.4 to 9.0±0.4	↑from 8.9±0.6 to 9.3±0.4
	weight	↓ 96.7±12.3 to 89.0±9.6 kg	↑from 92.9±10.4 to 98.2±6.3 kg
	Weight loss	Loss of 9.2±8.3% **	Gain of 9.2±3.9% **
	Waist circumfere nce	↓104.2±7.1 to 98.2±6.5 cm**	↑102.5±9.7 to 106±3.2 cm**
	Mortality	7.4%	16.1 %
	*(p<0.0005)	



Conclusion: Testosterone therapy prevented progression from prediabetes to T2DM in hypogonadal men while more than 40% of untreated hypogonadal men developed T2DM. This effect may have been mediated by weight loss and the invariable increase in lean mass achieved by testosterone.: